Mumbai, India and Beijing, China – May 22, 2026
Lupin Limited announced that China’s National Medical Products Administration (NMPA) has approved its Abbreviated New Drug Application (ANDA) for Oseltamivir Phosphate Oral Suspension developed in partnership with Yabao Pharmaceutical Co. The approval marks a significant milestone for Lupin as it officially enters the Chinese pharmaceutical market for the first time, strengthening the company’s global expansion strategy while increasing access to affordable influenza treatment options, particularly for paediatric patients.
The approved product, Oseltamivir Phosphate for Oral Suspension 6 mg/mL, is indicated for the treatment and prevention of influenza A and B infections. The oral suspension formulation is especially important for younger patients who may face challenges swallowing tablets or capsules, making the therapy highly relevant in paediatric healthcare settings. Industry experts believe the approval reinforces the growing importance of international pharmaceutical collaborations in expanding access to essential anti-infective medicines across Asia.
Lupin Expands Global Presence Through China Entry
The China approval represents a strategic breakthrough for Lupin, which has built a strong global presence across more than 100 international markets. By entering China — one of the world’s largest and fastest-growing pharmaceutical markets — Lupin aims to strengthen its long-term international business footprint while leveraging local partnerships to accelerate commercialization opportunities.
The company confirmed that the product will be commercialized through its collaboration with Yabao Pharmaceuticals, a leading Chinese pharmaceutical company with strong expertise in paediatric medicines and extensive domestic distribution capabilities. Executives from both companies described the approval as a major achievement that demonstrates their shared commitment to improving patient access to high-quality, affordable therapies.
Advertisement
According to Lupin, Oseltamivir Oral Suspension is approved for the treatment of influenza A and B in patients aged two weeks and older, as well as for the prevention of influenza in individuals one year of age and older. The availability of a pediatric-friendly oral suspension formulation is expected to play an important role during seasonal influenza outbreaks, especially among children and vulnerable populations.
Lupin leadership emphasized that the partnership with Yabao reflects a broader strategy focused on expanding therapeutic access in key international markets while strengthening collaborations with established regional pharmaceutical companies. Analysts noted that China’s large population, growing healthcare infrastructure, and increasing demand for high-quality generic medicines create significant commercial opportunities for global pharmaceutical manufacturers.
Partnership Strengthens Pediatric and Anti-Infective Portfolio
Yabao Pharmaceutical stated that the approval further strengthens its commitment to expanding access to quality paediatric medicines in China. The company has long maintained a strong presence in the Chinese paediatric healthcare sector and continues to expand its research and development capabilities in both pediatric and adult chronic disease therapies.
Industry observers believe the partnership between Lupin and Yabao combines global pharmaceutical manufacturing expertise with strong local regulatory and commercialization capabilities. Yabao’s experience in pediatric formulations and market distribution may help accelerate adoption of the oral suspension therapy across hospitals, clinics, and pharmacies throughout China.
Oseltamivir remains one of the most widely used antiviral medicines for influenza management globally. Early treatment with oseltamivir has been shown to reduce symptom severity and complications associated with influenza infection, particularly in children, elderly patients, and individuals at high risk of complications. The oral suspension formulation provides greater dosing flexibility and ease of administration for younger age groups, supporting broader treatment accessibility.
Global Generic Drug Competition Continues to Grow
The approval also highlights the increasing role of generic pharmaceutical companies in supporting global healthcare access through cost-effective alternatives to branded therapies. Lupin continues to strengthen its portfolio across respiratory, cardiovascular, anti-diabetic, gastrointestinal, anti-infective, and women’s health therapies while expanding investments in biotechnology products and complex generics.
With more than 15 manufacturing facilities and seven research centers worldwide, Lupin has steadily expanded its global pharmaceutical operations. Analysts believe the company’s successful entry into China could open additional opportunities for future product launches and partnerships within the country’s rapidly evolving healthcare sector.
The approval further underscores the growing demand for pediatric-focused drug formulations and accessible anti-infective therapies as healthcare systems worldwide continue prioritizing infectious disease preparedness and seasonal influenza management.
Source: Lupin press release
